Results 31 to 40 of about 23,625 (204)

Optical control of L-Type Ca2+ channels using a diltiazem photoswitch [PDF]

open access: yes, 2018
L-type Ca2+ channels (LTCCs) play a crucial role in excitation-contraction couplingand the release of hormones from secretory cells. They are targets of numerousantihypertensive and antiarrhythmic drugs such as diltiazem.
Timm Fehrentz   +32 more
core   +1 more source

Pharmacokinetics and Hypotensive Effect of Diltiazem in Rabbits: Comparison of Diltiazem with its Major Metabolites

open access: yes, 1998
To assess the contribution of its metabolites to the antihypertensive effects of diltiazem, a previously established rabbit model has been used to compare the pharmacokinetics and haemodynamic effects of the drug with those of its major metabolites ...
Joe D Z Feng   +2 more
core   +1 more source

Comparison of nebivolol versus diltiazem in improving coronary artery spasm and quality of life in patients with hypertension and vasospastic angina: A prospective, randomized, double-blind pilot study

open access: yesPLoS ONE, 2020
Background Beta-blockers are often not the preferred treatment for patients with vasospastic angina. However, nebivolol, beta-blocker with nitric oxide-releasing effect, could theoretically improve coronary vasospasm.
Hyungdon Kook   +6 more
doaj   +2 more sources

The EMA Qualification Opinion for CYP Inhibition‐Mediated Drug–Drug Interaction Predictions: Implications for PBPK Credibility Assessment in the Era of ICH M15

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clinical pharmacology and pharmacometrics teams are now being encouraged to implement the ICH M15 framework in drug development to support model‐informed decisions in regulatory submissions. Although model performance is an important component of model evaluation, regulatory confidence also depends on the intended context of use (CoU) and the ...
Karen Rowland Yeo   +6 more
wiley   +1 more source

Reports of Erythematous Macular Skin Eruptions Associated with Diltiazem Therapy

open access: yes, 1990
Diltiazem is a commonly prescribed calcium-channel antagonist for hypertension and ischemic heart disease. The incidence of rash associated with diltiazem therapy is reported to be 1.3 percent.
Douglas R. Geraets, Stewart R. Wirebaugh
core   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Subcorneal Pustular Dermatosis, a Systematic Review and Pooled Analysis of a Rare and Underdiagnosed Disease

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives To summarise the demographic, clinical, histopathological, management and disease course of SPD.
Mason H. Crossman   +5 more
wiley   +1 more source

An Expired Non-Toxic Diltiazem Hydrochloride as Corrosion Inhibitor for Cu in Nitric Acid Medium

open access: yesInternational Journal of Electrochemical Science, 2017
The corrosion inhibition of Cu in 1 M HNO3 solution by expired Diltiazem Hydrochloride (HD) has been tested by Tafel polarization, electrical frequency modulation, electrical impedance spectroscopy, and mass loss method. The Diltiazem Hydrochloride gives
A.S. Fouda   +3 more
doaj   +1 more source

Rate control with intravenous diltiazem, verapamil, and metoprolol in acute atrial fibrillation with rapid ventricular rate

open access: yesSAGE Open Medicine, 2021
Introduction: Diltiazem is a preferred agent for rate control in atrial fibrillation due to its quick onset, minimal side effects, and low cost. Due to its intermittent national shortage since February 2018, the utilization of intravenous metoprolol and ...
Tia Medeiros   +4 more
doaj   +1 more source

Diltiazem-cyclosporin pharmacokinetic interaction - dose-response relationship.

open access: yes, 1997
Aims: To study the dose-response relationship of the pharmacokinetic interaction between diltiazem and cyclosporin in kidney transplant recipients. Methods: Eight stable kidney transplant recipients maintained on cyclosporin but not taking diltiazem ...
Mathew, T., Morris, R., Jones, T.
core   +1 more source

Home - About - Disclaimer - Privacy